Novavax stock tanks on report of COVID-19 vaccine manufacturing troubles
The potential production problems with Novavax's vaccine could hamper the efforts of the COVAX initiative, which forecast in September that it will be able to provide low and middle-income countries 1.425 billion COVID-19 vaccine doses to by the end of the year and 2 billion doses by the first quarter of 2022.
https://ift.tt/3lW44Td
Post a Comment